Single dose oral dexamethasone versus multi-dose prednisolone in the treatment of acute exacerbations of asthma in children who attend the emergency department: study protocol for a randomized controlled trial

2.50
Hdl Handle:
http://hdl.handle.net/10147/251400
Title:
Single dose oral dexamethasone versus multi-dose prednisolone in the treatment of acute exacerbations of asthma in children who attend the emergency department: study protocol for a randomized controlled trial
Authors:
Cronin, John; Kennedy, Una; McCoy, Siobhan; an Fhailí, Sinéad N; Crispino-O’Connell, Gloria; Hayden, John; Wakai, Abel; Walsh, Sean; O’Sullivan, Ronan
Citation:
Trials. 2012 Aug 21;13(1):141
Issue Date:
21-Aug-2012
URI:
http://dx.doi.org/10.1186/1745-6215-13-141; http://hdl.handle.net/10147/251400
Abstract:
Abstract Background Asthma is a major cause of pediatric morbidity and mortality. In acute exacerbations of asthma, corticosteroids reduce relapses, subsequent hospital admission and the need for ß2-agonist therapy. Prednisolone is relatively short-acting with a half-life of 12 to 36 hours, thereby requiring daily dosing. Prolonged treatment course, vomiting and a bitter taste may reduce patient compliance with prednisolone. Dexamethasone is a long-acting corticosteroid with a half-life of 36 to 72 hours. It is used frequently in children with croup and bacterial meningitis, and is well absorbed orally. The purpose of this trial is to examine whether a single dose of oral dexamethasone (0.3 mg/kg) is clinically non-inferior to prednisolone (1 mg/kg/day for three days) in the treatment of exacerbations of asthma in children who attend the Emergency Department. Methods/design This is a randomized, non-inferiority, open-label clinical trial. After informed consent with or without assent, patients will be randomized to either oral dexamethasone 0.3 mg/kg stat or prednisolone 1 mg/kg/day for three days. The primary outcome measure is the comparison between the Pediatric Respiratory Assessment Measure (PRAM) across both groups on Day 4. The PRAM score, a validated, responsive and reliable tool to determine asthma severity in children aged 2 to 16 years, will be performed by a clinician blinded to treatment allocation. Secondary outcomes include relapse, hospital admission and requirement for further steroid therapy. Data will be analyzed on an intention-to-treat and a per protocol basis. With a sample size of 232 subjects (105 in each group with an estimated 10% loss to follow-up), we will be able to reject the null hypothesis - that the population means of the experimental and control groups are equal with a probability (power) of 0.9. The Type I error probability associated with this test (of the null hypothesis) is 0.05. Discussion This clinical trial may provide evidence that a shorter steroid course using dexamethasone can be used in the treatment of acute pediatric asthma, thus eliminating the issue of compliance to treatment. Registration ISRCTN26944158 and EudraCT Number 2010-022001-18
Item Type:
Journal Article

Full metadata record

DC FieldValue Language
dc.contributor.authorCronin, John-
dc.contributor.authorKennedy, Una-
dc.contributor.authorMcCoy, Siobhan-
dc.contributor.authoran Fhailí, Sinéad N-
dc.contributor.authorCrispino-O’Connell, Gloria-
dc.contributor.authorHayden, John-
dc.contributor.authorWakai, Abel-
dc.contributor.authorWalsh, Sean-
dc.contributor.authorO’Sullivan, Ronan-
dc.date.accessioned2012-11-08T10:08:32Z-
dc.date.available2012-11-08T10:08:32Z-
dc.date.issued2012-08-21-
dc.identifier.citationTrials. 2012 Aug 21;13(1):141-
dc.identifier.urihttp://dx.doi.org/10.1186/1745-6215-13-141-
dc.identifier.urihttp://hdl.handle.net/10147/251400-
dc.description.abstractAbstract Background Asthma is a major cause of pediatric morbidity and mortality. In acute exacerbations of asthma, corticosteroids reduce relapses, subsequent hospital admission and the need for ß2-agonist therapy. Prednisolone is relatively short-acting with a half-life of 12 to 36 hours, thereby requiring daily dosing. Prolonged treatment course, vomiting and a bitter taste may reduce patient compliance with prednisolone. Dexamethasone is a long-acting corticosteroid with a half-life of 36 to 72 hours. It is used frequently in children with croup and bacterial meningitis, and is well absorbed orally. The purpose of this trial is to examine whether a single dose of oral dexamethasone (0.3 mg/kg) is clinically non-inferior to prednisolone (1 mg/kg/day for three days) in the treatment of exacerbations of asthma in children who attend the Emergency Department. Methods/design This is a randomized, non-inferiority, open-label clinical trial. After informed consent with or without assent, patients will be randomized to either oral dexamethasone 0.3 mg/kg stat or prednisolone 1 mg/kg/day for three days. The primary outcome measure is the comparison between the Pediatric Respiratory Assessment Measure (PRAM) across both groups on Day 4. The PRAM score, a validated, responsive and reliable tool to determine asthma severity in children aged 2 to 16 years, will be performed by a clinician blinded to treatment allocation. Secondary outcomes include relapse, hospital admission and requirement for further steroid therapy. Data will be analyzed on an intention-to-treat and a per protocol basis. With a sample size of 232 subjects (105 in each group with an estimated 10% loss to follow-up), we will be able to reject the null hypothesis - that the population means of the experimental and control groups are equal with a probability (power) of 0.9. The Type I error probability associated with this test (of the null hypothesis) is 0.05. Discussion This clinical trial may provide evidence that a shorter steroid course using dexamethasone can be used in the treatment of acute pediatric asthma, thus eliminating the issue of compliance to treatment. Registration ISRCTN26944158 and EudraCT Number 2010-022001-18-
dc.titleSingle dose oral dexamethasone versus multi-dose prednisolone in the treatment of acute exacerbations of asthma in children who attend the emergency department: study protocol for a randomized controlled trial-
dc.typeJournal Article-
dc.language.rfc3066en-
dc.rights.holderJohn Cronin et al.; licensee BioMed Central Ltd.-
dc.description.versionPeer Reviewed-
dc.date.updated2012-11-08T00:03:45Z-
All Items in Lenus,the Irish health repository are protected by copyright, with all rights reserved, unless otherwise indicated.